Table 1 Demographic and clinical characteristics of participants

From: Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer’s disease

 

Whole sample

rs73069071 b

ADNI-GO/2

(n=678)

C-allele (n=156)

TT (n=522)

 Age (years) (mean ±s.d.)

72.5±7.3

72.8±7.1

72.4±7.4

 Sex (% Female)

45%

40%

46%

 Education (years) (mean ±s.d.)

16.2±2.6

16.4±2.6

16.2±2.6

 APOE ɛ4-carrier %

45%

45%

45%

 Diagnosis (CNa/EMCI/LMCI/AD) %

29/37/18/16

25/40/21/14

30/37/17/16

 ADAS-cog score

10.2±6.9

10.1±5.6

10.3±7.3

 MMSE score

27.5±2.6

27.8±2.4

27.5±2.7

 Cortical Aβ ([18F]Florbetapir-PET)

1.2±0.23

1.2±0.25

1.2±0.22

ADNI-1

(n=165)

C-allele (n=34)

TT (n=131)

 Age (mean±s.d.)

79.4±6.1

81.3±4.7

78.9±6.3

 Sex (% Female)

36%

35%

37%

 Education (years) (mean ±s.d.)

16.0±3.0

16.3±3.0

16.0±3.0

 APOE ɛ4-carrier %

38%

26%

40%

 Diagnosis (CN/MCI/AD) %

42/32/27

38/32/30

43/31/26

 ADAS-cog score

11.3±9.3

12.0±7.8

11.2±9.6

 MMSE score

26.5±4.4

26.4±3.7

26.6±4.6

 Cortical Aβ ([18F]Florbetapir-PET)

1.2±0.23

1.2±0.25

1.2±0.23

ROS/MAP

(n=782)

C-allele (n=193)

TT (n=589)

 Study (ROS/MAP)

396/386

98/95

298/291

 Age (mean ±s.d.)

87.7±6.5

88.0±6.8

87.6±6.5

 Sex (% Female)

62%

59%

63%

 Education (years) (mean ±s.d.)

16.1±3.1

16.1±3.1

16.1±3.1

 APOE ɛ4-carrier %

22%

23%

22%

 Diagnosis (CN/MCI/AD) %

40/29/31

36/28/36

41/30/29

 Global cognition Z-score

−0.7±1.1

−0.8±1.1

−0.7±1.1

 MMSE score

23.3±7.3

22.4±7.8

23.6±7.1

 Cortical Aβ (IHC)

3.8±4.2

4.0±4.1

3.7±4.1

  1. Abbreviations: Aβ, beta-amyloid; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s disease assessment scale—cognitive subscale; CN, healthy controls; EMCI, early mild cognitive impairment; IHC, immunohistochemistry; LMCI, late mild cognitive impairment; MCI, mild cognitive impairment; MMSE, mini-mental state examination; PET, positron emission tomography.
  2. aCognitively healthy controls with and without significant memory concern are grouped together as CN.
  3. bGiven the low number of CC homozygotes in each sample (ADNI-GO/2: n=11; ADNI-1: n=4; ROS/MAP: n=5), CC and TC carriers are grouped together for the convenience of comparison. Rs73069071 minor-allele frequency is similar in all three samples (ADNI-GO/2: 12.3%; ADNI-1: 11.5%; ROS/MAP: 12.7%).
Back to article page